1 |
MARON B J, DESAI M Y, NISHIMURA R A, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 79(4): 372-389.
|
2 |
OMMEN S R, MITAL S, BURKE M A, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2020, 76(25): 3022-3055.
|
3 |
MARON B J, GARDIN J M, FLACK J M, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study[J]. Circulation, 1995, 92(4): 785-789.
|
4 |
HO C Y, CHARRON P, RICHARD P, et al. Genetic advances in sarcomeric cardiomyopathies: state of the art[J]. Cardiovasc Res, 2015, 105(4): 397-408.
|
5 |
TEEKAKIRIKUL P, ZHU W J, HUANG H C, et al. Hypertrophic cardiomyopathy: an overview of genetics and management[J]. Biomolecules, 2019, 9(12): 878.
|
6 |
RICHARDS E M, LI J, STEVENS B R, et al. Gut microbiome and neuroinflammation in hypertension[J]. Circ Res, 2022, 130(3): 401-417.
|
7 |
CANDELLI M, FRANZA L, CIANCI R, et al. The interplay between Helicobacter pylori and gut microbiota in non-gastrointestinal disorders: a special focus on atherosclerosis[J]. Int J Mol Sci, 2023, 24(24): 17520.
|
8 |
TANG W H W, NEMET I, LI X S, et al. Prognostic value of gut microbe-generated metabolite phenylacetylglutamine in patients with heart failure[J]. Eur J Heart Fail. 2023. doi: 10.1002/ejhf.3111.
|
9 |
ORGAN C L, OTSUKA H, BHUSHAN S, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure[J]. Circ Heart Fail, 2016, 9(1): e002314.
|
10 |
SHIH D M, WANG Z N, LEE R, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis[J]. J Lipid Res, 2015, 56(1): 22-37.
|
11 |
LI Z H, WU Z Y, YAN J Y, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis[J]. Lab Invest, 2019, 99(3): 346-357.
|
12 |
GREEN E M, WAKIMOTO H, ANDERSON R L, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science, 2016, 351(6273): 617-621.
|
13 |
RYU Y, JIN L, KEE H J, et al. Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity[J]. Sci Rep, 2016, 6: 34790.
|
14 |
TANG W H, WANG Z N, FAN Y Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis[J]. J Am Coll Cardiol, 2014, 64(18): 1908-1914.
|
15 |
DOBREV D, WEHRENS X H T. Role of RyR2 phosphorylation in heart failure and arrhythmias: controversies around ryanodine receptor phosphorylation in cardiac disease[J]. Circ Res, 2014, 114(8): 1311-1319; discussion1319.
|
16 |
CHANDRA M, RUNDELL V L, TARDIFF J C, et al. Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T[J]. Am J Physiol Heart Circ Physiol, 2001, 280(2): H705-H713.
|
17 |
NAJAFI A, SCHLOSSAREK S, VAN DEEL E D, et al. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice[J]. Pflugers Arch, 2015, 467(6): 1303-1317.
|
18 |
HOUSER S R. Role of RyR2 phosphorylation in heart failure and arrhythmias: protein kinase A-mediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmias[J]. Circ Res, 2014, 114(8): 1320-1327; discussion1327.
|
19 |
LEHNART S E, WEHRENS X H T, REIKEN S, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias[J]. Cell, 2005, 123(1): 25-35.
|
20 |
BETOCCHI S, HESS O M, LOSI M A, et al. Regional left ventricular mechanics in hypertrophic cardiomyopathy[J]. Circulation, 1993, 88(5 Pt 1): 2206-2214.
|
21 |
MARAS D, CHUNG R, DUNCAN A, et al. Patterns of cardiac dysfunction coinciding with exertional breathlessness in hypertrophic cardiomyopathy[J]. Int J Cardiol, 2013, 170(2): 233-238.
|